Co-Diagnostics, Inc. CODX
Co-Diagnostics, Inc. (Nasdaq: CODX) is an infectious disease diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Co-Dx PCR Pro platform with Flu A/B and RSV multiplex test | upper respiratory infection | unclear | NA_NON_THERAPEUTIC |
| Logix Smart PCR test suite (lab-based) | COVID-19, TB, HPV, hepatitis, other infectious disease | unclear | NA_NON_THERAPEUTIC |
| TB test on Co-Dx PCR platform | tuberculosis | unclear | NA_NON_THERAPEUTIC |
| HPV test on Co-Dx PCR platform | human papillomavirus | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.